Go online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guidelines supporting a treatment role for targeted agents, including BTK and BCL-2 inhibitors, in the management of B-cell malignancies, Identify the unique spectrum of adverse events associated with the use of targeted agents in B-cell malignancies, including hypertension, bleeding, cardiac events, TLS, neutropenia, fatigue, and others, Develop team-based management strategies to address the emergence of adverse events in patients with B-cell malignancies receiving therapy with novel agents, Utilize team-based educational and counseling strategies detailing therapeutic and safety expectations for patients with MCL, CLL, or other B-cell malignancies.